Navigation Links
Renova Therapeutics leadership speaking at Cell & Gene Therapy CEO forum and Boulder Peptide Symposium

SAN DIEGO, Sept. 25, 2017 /PRNewswire-USNewswire/ -- Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced that the company's CEO and Co-founder, Jack W. Reich, Ph.D., is participating on a panel at the Cell & Gene Therapy CEO forum in Boston, and its Vice President of Preclinical Research and Pharmacology, Peter Gengo, Ph.D., is speaking at the Boulder Peptide Symposium in Boulder, Colorado. Both events are occurring on September 25.

Cell & Gene Therapy CEO

Jack W. Reich, Ph.D., CEO & Co-founder of Renova Therapeutics
Jack W. Reich, Ph.D., CEO & Co-founder of Renova Therapeutics
Peter Gengo, Ph.D., Vice President of Preclinical Research and Pharmacology at Renova Therapeutics
Peter Gengo, Ph.D., Vice President of Preclinical Research and Pharmacology at Renova Therapeutics

Boston Biotech Conferences' Cell & Gene Therapy CEO is an off-the-record networking forum that brings together CEOs and decision-makers in cell therapy, gene therapy and regenerative medicine. Dr. Reich will be participating on a discussion panel on overcoming technology challenges in cell and gene therapy companies.

"Since the inception of gene therapy, we've seen tremendous progress in the field over the last few decades – but no disruptive medical innovation is without its challenges," said Dr. Reich, who was previously co-founder of the first gene therapy company, Viagene, and co-founder of Collateral Therapeutics, the first gene therapy company focused on cardiovascular disease. "With gene therapy, we're looking at changing the way some major chronic diseases are treated in an unprecedented manner. There are lessons we've all learned along the way that are worth sharing."

The forum comprises intimate discussion panels, keynotes and fireside chats with thought leaders debating business model efficiencies, financing, regulatory issues, market access and reimbursement, novel partnerships, manufacturing and delivery challenges. Healthcare investors and leading researchers also participate.

The meeting also features speakers from GlaxoSmithKline, Novartis and Pfizer, among others. The panel on overcoming technology challenges will take place at 11:30 a.m. EST.

Boulder Peptide Symposium

The Boulder Peptide Symposium is an annual event in which key decision leaders from both industry and academia come together to discuss the future of peptide therapeutics.

An accomplished biochemical analytical pharmacologist, Dr. Gengo is presenting the Renova Therapeutics gene and peptide therapy programs at the symposium. In particular, he will provide an overview of the company's discovery work on peptides as potential treatment options for heart failure as well as type 2 diabetes.

"Complementing the Renova Therapeutics gene-based product candidate portfolio are peptide-based programs that can help impact the symptoms and progression of major chronic diseases," said Dr. Gengo. "Right now we're looking at identifying peptide variants that could become subcutaneous or intravenous infusion therapies to ease suffering of heart failure or type 2 diabetes patients."

Dr. Gengo joined Renova Therapeutics in May to direct and execute the company's preclinical objectives, including developing a stresscopin-based peptide product candidate program. Along with Waldemar Radziszewski, MD, Ph.D., Renova's Executive Vice President of Translational Research, Dr. Gengo worked on the stresscopin development program for acute heart failure while at Janssen Pharmaceuticals.

Dr. Gengo's presentation will take place on September 25, the first day of the three-day symposium.

About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for heart failure and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with heart failure. The company's product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit

About the Boston Biotech Conferences
The Boston Biotech Conferences (BBC)'s mission is to build a vibrant community of bio-pharma leaders, which will help to drive innovation in biotech, and bring important drugs to patients more quickly. The conferences are exclusive, thought-leader forums for senior bio-pharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking and corporate development within the bio-pharma community. The meetings are invitation-only, off-the-record forums that bring together the past, present and future leaders in the healthcare community to network, exchange ideas and share insights into the industry's challenges and opportunities. For more information, visit

About the Boulder Peptide Symposium
The Boulder Peptide Symposium seeks to bring together key decision leaders from both industry and academia to discuss the future of peptide therapeutics. Peptide therapeutics are potent and highly selective yet their development into effective treatments can be challenged by limited delivery routes, product stability, manufacturing challenges and an evolving regulatory landscape. BPS is the key forum where these challenges will be identified, discussed, and one day—addressed.


View original content with multimedia:

SOURCE Renova Therapeutics
Copyright©2017 PR Newswire.
All rights reserved

Related biology technology :

1. Don't miss the I2SL High-Tech Talks Webinar Series Presenting: Butler University's Renovation With Filtered Fume Hoods, 3 Years Later
2. RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate
3. Temarry Recycling’s New $100,000 Waste to Energy Renovation
4. Renova Therapeutics expands clinical development team with latest hire
5. Biotech finance expert joins Renova Therapeutics as CFO
6. Renova Therapeutics secures novel AAV vector license for use in metabolic and cardiovascular gene therapy development
7. UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as keynote speaker for annual meeting
8. Industry leaders join Renova Therapeutics to lead preclinical programs into clinical development
9. Renova Therapeutics co-founder awarded highest research honor by the U.S. Department of Veterans Affairs
10. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
11. Novira Therapeutics Completes $25 Million Series A Financing
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):